New report calls for value-driven collaboration for design
and reimbursement of personalized medicine
New York, NY (June 13, 2012)
A new report calls for greater collaboration and replacing comparative effectiveness research with value-driven design of new products in order to preserve American leadership in medical innovation and personalized medicine.
“From Promise to Performance: Commercializing Personalized Medicine” was produced by The Personalized Medicine Acceleration Working Group. The working group is a project of The Center For Medicine In The Public Interest and was established to recommend new pathways for the faster commercialization of tools and technologies that deliver personalized medicine. The report and the working group were supported with a grant from the Ewing Marion Kauffman Foundation (www.Kauffman.org).
Robert M. Goldberg, PhD, a working group member and author of the report notes: “Medical progress has been a source of economic growth and prosperity for the United States. Personalized medicine, because of its capacity to extend life and prevent illness, will be a source of future value and wealth. However, the nation’s ability to commercialize such products has declined even as the capacity to do so has grown in countries such as China, India, and Brazil.”
The working group focused on how to design and reimburse new products that reflect increased value to consumers.
The working group recommends adopting a value-driven approach to the design and development of personalized medicine. Simply put, that means investing in design elements that make medicine easier and more effective for consumers or end-users and ensuring that proof-of-concepts and prototypes achieve that goal.
To do so, it recommends the refinement and use of a value-driven equation to measure improved patient-centricity and reduced complexity relative to the cost of using a new technology. Such an equation can take into account the preferences of health plans, consumers, and doctors prior to both FDA review and adoption. It is, therefore, an approach to measuring value for reimbursement purposes built into the design of products.
It also recommends that two institutions involved in the working group – The Scripps Translational Research Institute and the Austen Bioinnovation Institute of Akron – collaborate to create a usability lab that would use the value-driven equation and help entrepreneurs engage in value-driven design and engineering.
The working group recommends replacing the current approach government and health plans use to decide whether to pay for personalized medicine. Reimbursement processes come after FDA approval and do not measure the value of new personalized technologies to add to the value of health and increase simplicity. Value-driven design would build the needs and preferences of patients, health plans and physicians into the design of products.
A separate paper developed for the working group estimates that comparative effectiveness research (“CER”) may reduce the number of new medicines by 57 over the next 10 years and cause the United States to forgo nearly $10 trillion in health value.
The report – “From Promise To Performance: Commercializing Personalized Medicine” – can be downloaded here: http://cmpi.org/reports-newsletters/reports/from-promise-to-performance
The second report -- "Uncertain Innovation: The Effect of Comparative Effectiveness Research (CER) On Personalized Medicine" -- can be downloaded here: http://cmpi.org/reports-newsletters/reports/uncertain-innovation
Reporters interested in scheduling an interview with the authors of the report should contact CMPI Vice President Bob Goldberg at firstname.lastname@example.org or 212-417-9169.
The Center for Medicine in the Public Interest, a non-profit public policy group dedicated to research-based free market reforms for the health care industry.